v3.26.3
Stockholders’ Deficit
3 Months Ended
Sep. 30, 2026
Stockholders’ Deficit [Abstract]  
Stockholders’ deficit

Note 13 — Stockholders’ deficit

 

Common stock 

 

As of September 30, 2026 and June 30, 2026, the Company has 50,000,000 authorized shares of common stock, par value $0.0001 per share. As of September 30, 2026 and June 30, 2026, there are 7,074,907 and 7,041,192 shares of common stock outstanding, respectively.

 

Equity incentive plan  

 

On September 24, 2024, pursuant to the Equity Incentive Plan (the “EIP”), 1,454,019 shares of common stock, par value $0.0001 per share, of the Company were set aside and reserved for issuance of certain stock option award and certain restricted shares to certain of the Company’s employees and consultants. The EIP has a 4-year vesting schedule, of which, 25% will be vested after year 1 with the 1/16th of these shares will vest each quarter thereafter on the same day of the month as the grant date. The vesting of each RSU is subject to the employee’s continued employment and the consultant’s continued engagement through applicable vesting dates.

 

On July 31, 2025, the Company cancelled 9,574 unvested RSUs previously granted to one of its employees on November 5, 2024, due to termination of the employment.

 

In July and August 2026, an aggregate of 72,647 unvested RSUs previously granted were forfeited due to termination of employment, including the 55,159 RSUs held by the Company’s former consultants and the 17,488 RSUs held by the Company’s former Chief Technology Officer.

 

In August 2026, two of the Company’s employees elected to have 2,722 and 1,066 shares, respectively, withheld from their RSU awards upon vesting to satisfy their employee tax withholding obligations. Accordingly, the Company withheld an aggregate of 3,728 shares and settled the employees’ required tax withholding obligations using the fair value of such shares of $9,881, based on the Company’s stock price on the respective vesting date of $2.65 per share.

 

The RSUs are accounted for as equity awards and are measured at fair value based upon the grant date market value of the Company’s common stock. Compensation expense is recognized on a straight-line basis over the vesting service period of four years. Forfeitures are accounted for as they occur.

 

The following table presents the total stock-based compensation expenses included in each of the respective expense line items for the periods presented: 

 

    For the Three Months Ended  
    September 30,  
    2026     2025  
Selling expenses   $ 21,885     $ 66,864  
General and administrative expenses     151,557       172,598  
Research and development expenses     59,963       57,335  
Total stock-based compensation expenses   $ 233,405     $ 296,797  

 

The following table summarizes the activity for all restricted stock units during the three months ended September 30, 2026:

 

    Shares     Weight
average
grant date
fair value
    Total fair
value
    Weighted
average  
remaining
contractual
term
(in years)
 
Unvested at June 30, 2025     693,929     $ 7.21     $ 5,001,916       3.36  
Granted     -       -       -       -  
Vested     (260,595 )     7.22       (1,882,417 )     -  
Forfeited     (44,180 )     7.30       (322,514 )     -  
Unvested at June 30, 2026     389,154       7.19       2,796,985       2.36  
Granted     -       -       -       -  
Vested     (33,715 )     7.18       (242,137 )     -  
Forfeited     (76,375 )     7.30       (557,538 )     -  
Unvested at September 30, 2026 (Unaudited)     279,064     $ 7.16     $ 1,997,310       2.11  

 

As of September 30, 2026, there was $1,858,808 total unrecognized compensation cost related to unvested RSUs granted under the employee incentive plan. The total cost is expected to be recognized over a remaining period of 2.11 years. 

 

Warrants

 

In connection with the reverse recapitalization, each of 12,156,417 ACAC’s issued and outstanding warrants was converted automatically into one redeemable warrant of the Company, exercisable for one share of common stock of the Company at an exercise price of $11.50 per share. All of these warrants met the criteria for equity classification.

 

The Company may call the Warrants for redemption, in whole and not in part, at a price of $0.01 per Warrant:

 

  ● in whole and not in part;

 

  ● upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and

 

  ● if, and only if, the reported last sale price of the common stock equals or exceeds $16.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending three business days before the Company sends the notice of redemption to the warrant holders.

  

The summary of warrants activity is as follows:

 

    Warrants
Outstanding
    Common
Stock
Issuable
    Weighted
Average
Exercise
Price
    Average
Remaining
Contractual
Life
 
June 30, 2025     12,145,917       12,145,917     $ 11.50       4.24  
Granted     -       -     $ -       -  
Forfeited     -       -     $ -       -  
Exercised     -       -     $ -       -  
June 30, 2026     12,145,917       12,145,917     $ 11.50       3.24  
Granted     -       -     $ -       -  
Forfeited     -       -     $ -       -  
Exercised     -       -     $ -       -  
September 30, 2026 (Unaudited)     12,145,917       12,145,917     $ 11.50       2.99  

 

The Company accounted for the 12,145,917 Warrants assumed from the merger as equity instruments in accordance with ASC 480, Distinguishing Liabilities from Equity, and ASC 815-40, Derivatives and Hedging: Contracts in Entity’s Own Equity.  As of September 30, 2026 and June 30, 2026, the Warrants had no intrinsic value, as the Company’s stock price was below the strike price.